Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE - Get Free Report) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 34,500 shares, an increase of 46.2% from the May 15th total of 23,600 shares. Currently, 0.4% of the company's shares are short sold. Based on an average daily trading volume, of 21,200 shares, the days-to-cover ratio is currently 1.6 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new position in Prenetics Global Limited (NASDAQ:PRE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent quarter. 25.01% of the stock is currently owned by institutional investors and hedge funds.

Prenetics Global Stock Up 23.3%

Shares of Prenetics Global stock traded up $1.75 during trading on Thursday, hitting $9.26. The stock had a trading volume of 380,483 shares, compared to its average volume of 20,617. Prenetics Global has a 1 year low of $3.09 and a 1 year high of $11.99. The stock has a 50 day simple moving average of $6.59 and a 200 day simple moving average of $5.58. The company has a market capitalization of $112.97 million, a PE ratio of -2.32 and a beta of 0.17.

Prenetics Global (NASDAQ:PRE - Get Free Report) last posted its quarterly earnings data on Thursday, June 12th. The company reported ($0.80) earnings per share for the quarter. Prenetics Global had a negative return on equity of 28.07% and a negative net margin of 115.91%. The firm had revenue of $17.31 million for the quarter. As a group, equities analysts expect that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.